Scholarlink

Introduction <p>Itch control is an important treatment goal for patients with atopic dermatitis (AD). According to the treat-to-target framework, optimal treatment goals in AD were defined for various disease domains (e.g., achievement of Eczema Area and Severity Index [EASI] ≤ 7, Peak Pruritus Numeric Rating Scale [PP-NRS] ≤ 4, and Dermatology Life Quality Index [DLQI] ≤ 5) to be achieved after 6&#xa0;months and sustained thereafter.</p> Methods <p>In this post hoc analysis of LIBERTY AD CHRONOS (NCT02260986), we report the proportion of patients achieving an optimal itch response with or without an optimal response in signs (EASI ≤ 7) and quality of life (DLQI ≤ 5), after 24 and 52&#xa0;weeks of treatment with dupilumab.</p> Results <p>The majority of patients (69 of 90; 76.7%) had an optimal itch response at week&#xa0;24 as measured by treat-to-target goal PP-NRS ≤ 4; this proportion was sustained at week&#xa0;52 (64 of 79; 81.0%). Using SCORing Atopic Dermatitis (SCORAD) Pruritus Visual Analog Scale (VAS) &lt; 4 as validation, the majority of patients (76/89; 85.4%) had an optimal itch response at week&#xa0;24, and this proportion was also sustained at week&#xa0;52 (69 of 79; 87.3%). Around 70% of patients with an optimal itch response according to PP-NRS or SCORAD Pruritus VAS also had optimal response in EASI and DLQI at weeks&#xa0;24 and 52.</p> Conclusion <p>Dupilumab provided optimal itch response and further optimal treatment response in signs and quality of life at week&#xa0;24, sustained up to 52&#xa0;weeks, in the majority of patients. Graphical Abstract available for this article.</p> Trial Registration <p>NCT02260986.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月19日

查看全文
  • Sonja Ständer,
  • Gil Yosipovitch,
  • Brian S. Kim,
  • Martin Steinhoff,
  • April Armstrong,
  • Franz J. Legat,
  • Kenji Kabashima,
  • Takeshi Nakahara,
  • Atsuyuki Igarashi,
  • Amy H. Praestgaard,
  • Tien V. Nguyen,
  • Mike Bastian

摘要

Introduction

Itch control is an important treatment goal for patients with atopic dermatitis (AD). According to the treat-to-target framework, optimal treatment goals in AD were defined for various disease domains (e.g., achievement of Eczema Area and Severity Index [EASI] ≤ 7, Peak Pruritus Numeric Rating Scale [PP-NRS] ≤ 4, and Dermatology Life Quality Index [DLQI] ≤ 5) to be achieved after 6 months and sustained thereafter.

Methods

In this post hoc analysis of LIBERTY AD CHRONOS (NCT02260986), we report the proportion of patients achieving an optimal itch response with or without an optimal response in signs (EASI ≤ 7) and quality of life (DLQI ≤ 5), after 24 and 52 weeks of treatment with dupilumab.

Results

The majority of patients (69 of 90; 76.7%) had an optimal itch response at week 24 as measured by treat-to-target goal PP-NRS ≤ 4; this proportion was sustained at week 52 (64 of 79; 81.0%). Using SCORing Atopic Dermatitis (SCORAD) Pruritus Visual Analog Scale (VAS) < 4 as validation, the majority of patients (76/89; 85.4%) had an optimal itch response at week 24, and this proportion was also sustained at week 52 (69 of 79; 87.3%). Around 70% of patients with an optimal itch response according to PP-NRS or SCORAD Pruritus VAS also had optimal response in EASI and DLQI at weeks 24 and 52.

Conclusion

Dupilumab provided optimal itch response and further optimal treatment response in signs and quality of life at week 24, sustained up to 52 weeks, in the majority of patients. Graphical Abstract available for this article.

Trial Registration

NCT02260986.

Graphical Abstract